Literature DB >> 23494182

Polo-like kinase 1 is overexpressed in renal cancer and participates in the proliferation and invasion of renal cancer cells.

Guojun Zhang1, Zhe Zhang, Zhuogang Liu.   

Abstract

Polo-like kinase 1 (Plk1) is an interesting molecule both as a biomarker and as a target for highly specific cancer therapy for several reasons. However, the functional significance of Plk1 in renal cell carcinoma (RCC) has not been reported. To explore whether Plk1 plays a general role in renal carcinoma, we examined the expression of Plk1 protein in renal urothelial carcinoma and cell lines, and analyzed the relationship between Plk1 protein expression and development, proliferation, and invasion of renal carcinoma. Immunohistochemisty was used to detect the expression of Plk1 in 100 renal carcinoma tissues. Moreover, the expression of Plk1 was analyzed by western blot and real-time polymerase chain reaction (PCR) in 80 renal carcinoma tissues and 20 normal renal tissues. CCK-8 assay, colony formation assay, and Transwell assay were used to examine proliferation and invasion ability of renal cancer cells with treatment of scytonemin (the specific inhibitor of Plk1). Statistical analysis was used to discuss the association between Plk1 expression and clinicopathologic parameters, and proliferation and invasion ability of renal cancer cells. Plk1 expressions were greater in cancerous tissues than in normal tissues (P<0.05). With an increase in tumor grade and stage, tumor metastasis, and recurrence, the level of Plk1 increased significantly in renal cancerous tissues. Moreover, there was a significantly higher expression of Plk1 in higher degree of malignant renal adenocarcinoma cell ACHN than that in renal adenocarcinoma cell 769-P. With increasing concentration of scytonemin, we found that cell proliferation and invasion activity decreased significantly. Plk1 expression status was closely correlated with important histopathologic characteristics (grades, stages, metastasis, and recurrence) of renal carcinomas. Furthermore, Plk1 played an important function on renal cancer cells' proliferation and invasion.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23494182     DOI: 10.1007/s13277-013-0732-0

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  23 in total

Review 1.  Polo-like kinase 1 inhibitors and their potential role in anticancer therapy, with a focus on NSCLC.

Authors:  René H Medema; Chia-Chi Lin; James Chih-Hsin Yang
Journal:  Clin Cancer Res       Date:  2011-10-15       Impact factor: 12.531

2.  Plk1-dependent phosphorylation of optineurin provides a negative feedback mechanism for mitotic progression.

Authors:  David Kachaner; Josina Filipe; Emmanuel Laplantine; Angela Bauch; Keiryn L Bennett; Giulio Superti-Furga; Alain Israël; Robert Weil
Journal:  Mol Cell       Date:  2012-02-24       Impact factor: 17.970

3.  Study of the docking-dependent PLK1 phosphorylation of the CDC25B phosphatase.

Authors:  Valérie Lobjois; Carine Froment; Emmanuelle Braud; Fanny Grimal; Odile Burlet-Schiltz; Bernard Ducommun; Jean-Pierre Bouche
Journal:  Biochem Biophys Res Commun       Date:  2011-05-27       Impact factor: 3.575

4.  Polo-like kinase 1: a potential therapeutic option in combination with conventional chemotherapy for the management of patients with triple-negative breast cancer.

Authors:  Virginie Maire; Fariba Némati; Marion Richardson; Anne Vincent-Salomon; Bruno Tesson; Guillem Rigaill; Eléonore Gravier; Bérengère Marty-Prouvost; Leanne De Koning; Guillaume Lang; David Gentien; Aurélie Dumont; Emmanuel Barillot; Elisabetta Marangoni; Didier Decaudin; Sergio Roman-Roman; Alain Pierré; Francisco Cruzalegui; Stéphane Depil; Gordon C Tucker; Thierry Dubois
Journal:  Cancer Res       Date:  2012-11-09       Impact factor: 12.701

5.  Acquired cystic disease-associated renal cell carcinoma with gain of chromosomes 3, 7, and 16, gain of chromosome X, and loss of chromosome Y.

Authors:  Naoto Kuroda; Tomoyuki Shiotsu; Ondrej Hes; Michal Michal; Taro Shuin; Gang-Hong Lee
Journal:  Med Mol Morphol       Date:  2011-01-26       Impact factor: 2.309

6.  High expression of polo-like kinase 1 is associated with the metastasis and recurrence in urothelial carcinoma of bladder.

Authors:  Zhe Zhang; Guojun Zhang; Chuize Kong
Journal:  Urol Oncol       Date:  2011-12-20       Impact factor: 3.498

7.  Polo-like kinase-1 is a target of the DNA damage checkpoint.

Authors:  V A Smits; R Klompmaker; L Arnaud; G Rijksen; E A Nigg; R H Medema
Journal:  Nat Cell Biol       Date:  2000-09       Impact factor: 28.824

8.  Proliferation state and polo-like kinase1 dependence of tumorigenic colon cancer cells.

Authors:  Federica Francescangeli; Michele Patrizii; Michele Signore; Giulia Federici; Simone Di Franco; Alfredo Pagliuca; Marta Baiocchi; Mauro Biffoni; Lucia Ricci Vitiani; Matilde Todaro; Ruggero De Maria; Ann Zeuner
Journal:  Stem Cells       Date:  2012-09       Impact factor: 6.277

9.  Polo-like kinase 1 may regulate G2/M transition of mouse fertilized eggs by means of inhibiting the phosphorylation of Tyr 15 of Cdc2.

Authors:  Zhe Zhang; Wen-Hui Su; Chen Feng; Da-Hai Yu; Cheng Cui; Xiao-Yan Xu; Bing-Zhi Yu
Journal:  Mol Reprod Dev       Date:  2007-10       Impact factor: 2.609

Review 10.  Kinase inhibitors: a new class of antirheumatic drugs.

Authors:  Vasileios C Kyttaris
Journal:  Drug Des Devel Ther       Date:  2012-09-21       Impact factor: 4.162

View more
  23 in total

1.  Plk1 promotes the migration of human lung adenocarcinoma epithelial cells via STAT3 signaling.

Authors:  Weijuan Yan; Huijie Yu; Wei Li; Fengsheng Li; Sinian Wang; Nan Yu; Qisheng Jiang
Journal:  Oncol Lett       Date:  2018-09-14       Impact factor: 2.967

2.  Plk1 inhibition leads to a failure of mitotic division during the first mitotic division in pig embryos.

Authors:  Zixiao Zhang; Changchao Chen; Panpan Cui; Yaya Liao; Lingyun Yao; Yue Zhang; Rong Rui; Shiqiang Ju
Journal:  J Assist Reprod Genet       Date:  2017-01-10       Impact factor: 3.412

3.  Evaluation of NIN/RPN12 binding protein inhibits proliferation and growth in human renal cancer cells.

Authors:  Jian-wei Jia; Ai-qin Liu; Yun Wang; Fen Zhao; Li-ling Jiao; Jun Tan
Journal:  Tumour Biol       Date:  2014-11-26

4.  PLK1 promotes epithelial-mesenchymal transition and metastasis of gastric carcinoma cells.

Authors:  Xiao Peng Cai; Liang Dong Chen; Hai Bin Song; Chun Xiao Zhang; Ze Wei Yuan; Zhen Xian Xiang
Journal:  Am J Transl Res       Date:  2016-10-15       Impact factor: 4.060

5.  PLK1 is a binding partner and a negative regulator of FOXO3 tumor suppressor.

Authors:  Octavian Bucur; Andreea Lucia Stancu; Maria Sinziana Muraru; Armelle Melet; Stefana Maria Petrescu; Roya Khosravi-Far
Journal:  Discoveries (Craiova)       Date:  2014 Apr-Jun

6.  PLK-1 Expression is Associated with Histopathological Response to Neoadjuvant Therapy of Hepatic Metastasis of Colorectal Carcinoma.

Authors:  M J Fernández-Aceñero; D Cortés; T Gómez del Pulgar; A Cebrián; L Estrada; J Martínez-Useros; A Celdrán; J García-Foncillas; C Pastor
Journal:  Pathol Oncol Res       Date:  2015-11-17       Impact factor: 3.201

Review 7.  Cross Talk between Wnt/β-Catenin and CIP2A/Plk1 Signaling in Prostate Cancer: Promising Therapeutic Implications.

Authors:  Ion Cristóbal; Federico Rojo; Juan Madoz-Gúrpide; Jesús García-Foncillas
Journal:  Mol Cell Biol       Date:  2016-05-31       Impact factor: 4.272

8.  Chromophobe renal cell carcinoma with and without sarcomatoid change: a clinicopathological, comparative genomic hybridization, and whole-exome sequencing study.

Authors:  Yuan Ren; Kunpeng Liu; Xueling Kang; Lijuan Pang; Yan Qi; Zhenyan Hu; Wei Jia; Haijun Zhang; Li Li; Jianming Hu; Weihua Liang; Jin Zhao; Hong Zou; Xianglin Yuan; Feng Li
Journal:  Am J Transl Res       Date:  2015-11-15       Impact factor: 4.060

9.  Targeting polo-like kinase 1 by NMS-P937 in osteosarcoma cell lines inhibits tumor cell growth and partially overcomes drug resistance.

Authors:  Valeria Sero; Elisa Tavanti; Serena Vella; Claudia Maria Hattinger; Marilù Fanelli; Francesca Michelacci; Rogier Versteeg; Barbara Valsasina; Beth Gudeman; Piero Picci; Massimo Serra
Journal:  Invest New Drugs       Date:  2014-09-07       Impact factor: 3.850

10.  FOXM1 participates in PLK1-regulated cell cycle progression in renal cell cancer cells.

Authors:  Zhe Zhang; Guojun Zhang; Chuize Kong
Journal:  Oncol Lett       Date:  2016-02-15       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.